Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07025031

Fetal Growth Restriction a Case Control Study

The study aims to investigate the responsible factors that leads to idiopathic fetal growth restriction.

Recruiting

Interested in participating?

Request Info

Key information

Age range

19 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia

Loading trial locations.

About this study

The study aims to investigate the relationship between maternal serum level of progesterone, immune-expression of HMOX-1 a placental angiogenesis marker with idiopathic fetal growth restriction.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • singleton
  • dated pregnancy

Exclusion criteria

  • fetus with structural or chromosomal anomaly
  • receive treatments such as aspirin, progestogen, low molecular weight heparin
  • has pre-existing medical disorders such as autoimmune disease, hypertension, diabetes
  • smoking
  • suspected intrauterine infection

Treatment and study plan

Primary outcomes

  1. Maternal serum level of progesterone

    Time frame: At the point of recruitment from 24 until 32 weeks gestation.

    Maternal blood will be withdrawn and serum isolated. Measurement of progesterone level will be performed from the serum sample using ELISA.

  2. Placental immunoexpression of Heme Oxygenase 1

    Time frame: At delivery within 24 until 38 weeks gestation.

    Immunoexpression of Heme Oxygenase 1 in syncytiotrophoblasts, cytotrophoblasts, fetal endothelial cells, maternal vessels and decidual cells.

Secondary outcomes

  1. Placenta histopathology examination

    Time frame: At delivery within 24 until 38 weeks gestation

    Placenta will be examined histopathologically

Study contacts

Contact information is provided by the study sponsor or research team.

Rahana Abd Rahman, MOG (UKM)

CONTACT

[email protected]

+60122719985 ext. 5964

Sponsors and collaborators

Lead sponsor

National University of Malaysia

Other

Registry information

Official study title

Maternal Serum Progesterone And Placental Heme Oxgenase-1 Expression In Early Onset Idiopathic Fetal Growth Restriction: A Case Control Study

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jun 17, 2025
Registry last updated
Jun 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.